REPLIGEN CORPORATION

NASDAQ: RGEN (Repligen Corporation)

Last update: 18 Mar, 1:20AM

152.81

2.19 (1.45%)

Previous Close 150.62
Open 150.42
Volume 434,220
Avg. Volume (3M) 617,018
Market Cap 8,580,067,328
Price / Earnings (Forward) 85.47
Price / Sales 12.19
Price / Book 4.00
52 Weeks Range
113.50 (-25%) — 200.23 (31%)
Earnings Date 29 Apr 2025 - 5 May 2025
Profit Margin -3.53%
Operating Margin (TTM) 5.59%
Diluted EPS (TTM) -0.420
Quarterly Revenue Growth (YOY) 10.40%
Quarterly Earnings Growth (YOY) 76.90%
Total Debt/Equity (MRQ) 34.44%
Current Ratio (MRQ) 6.79
Operating Cash Flow (TTM) 145.69 M
Levered Free Cash Flow (TTM) 183.66 M
Return on Assets (TTM) 0.92%
Return on Equity (TTM) -1.16%

Market Trend

Short Term Medium Term
Industry Medical Instruments & Supplies (US) Bearish Mixed
Medical Instruments & Supplies (Global) Bearish Mixed
Stock Repligen Corporation Bullish Bullish

AIStockmoo Score

1.5
Analyst Consensus 1.5
Insider Activity NA
Price Volatility 1.0
Technical Moving Averages 1.5
Technical Oscillators 2.0
Average 1.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
RGEN 9 B - - 4.00
ICUI 3 B - - 1.71
ATRC 2 B - - 3.59
BLFS 979 M - - 2.99
ATRI 807 M 0.48% 43.11 3.39
KRMD 105 M - - 7.55

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Sector Healthcare
Industry Medical Instruments & Supplies
Investment Style Small Core
% Held by Insiders 6.44%
% Held by Institutions 103.23%
52 Weeks Range
113.50 (-25%) — 200.23 (31%)
Price Target Range
150.00 (-1%) — 190.00 (24%)
High 190.00 (JP Morgan, 24.34%) Buy
Median 180.00 (17.79%)
Low 150.00 (Canaccord Genuity, -1.84%) Hold
Average 172.80 (13.08%)
Total 3 Buy, 2 Hold
Avg. Price @ Call 139.07
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 05 May 2025 180.00 (17.79%) Buy 141.51
21 Feb 2025 180.00 (17.79%) Buy 158.99
RBC Capital 30 Apr 2025 189.00 (23.68%) Buy 137.99
21 Feb 2025 205.00 (34.15%) Buy 158.99
JP Morgan 29 Apr 2025 190.00 (24.34%) Buy 139.43
21 Feb 2025 200.00 (30.88%) Buy 158.99
Canaccord Genuity 16 Apr 2025 150.00 (-1.84%) Hold 132.10
21 Feb 2025 170.00 (11.25%) Hold 158.99
Evercore ISI Group 18 Mar 2025 155.00 (1.43%) Hold 144.34

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria